Volume 2.19 | May 20

Mammary Cell News 2.19 May 20, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Scientists Identify Markers on Human Breast Cancer Cells Linked to Development of an Aggressive, But Less Common Form of Breast Cancer
Scientists have identified a group of surface markers on cells linked to an aggressive type of breast cancer called estrogen receptor-negative cancer. [Press release from the National Cancer Institute discussing online prepublication in Cancer Research]



STEMCELL Technologies with The Jackson Laboratories offers:

Mammary Stem Cell Training Course
Two-Day Lecture and Laboratory Series
June 29-30, 2010
The Jackson Laboratories, Maine, USA


New Research on Hormone Link to Breast Cancer, UK
Women who have high blood levels of a hormone called insulin-like growth factor-I (IGF-I) are more likely to develop breast cancer, according to a Cancer Research UK study. [Press release from Medical News Today discussing online prepublication in the Lancet Oncology]

Drug Now Used to Treat Erectile Dysfuncton may Enhance Delivery of Herceptin to Certain Brain Tumors
New research by scientists suggests that a drug currently approved to treat erectile dysfunction may significantly enhance the delivery of the anti-cancer drug Herceptin to certain hard-to-treat brain tumors. [Press release from EurekAlert! discussing online prepublication in PLoS ONE ]

Slight Changes in Two Key Genes Appear to Launch Breast Cancer Development
Researchers have been able to show, in mice, how just a little adjustment in the expression of two common genes can promote the kind of cellular changes that led to breast cancer. [Press release from Georgetown Lombardi Comprehensive Cancer Center discussing online prepublication in Cancer Research ]

Watch Procedure Now  
Use EpiCult-B® to Culture and Characterize
Human Mammary Epithelial Progenitors

by STEMCELL Technologies

CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)


CD44pos CD49fhi CD133/2hi Defines Xenograft-Initiating Cells in Estrogen Receptor-Negative Breast Cancer
Researchers show here that both CD44pos CD24neg and CD44pos CD24pos cell populations in estrogen receptor alpha-negative breast tumors are tumorigenic in murine xenograft models. They also describe a third population of xenograft-initiating cells enriched in CD44pos CD49fhi CD133/2hi cells that display heightened tumorigenicity, self-renewal in vivo, and the capacity to give rise to functional and molecular heterogeneity. [Cancer Res]

The Fbw7 Tumor Suppressor Targets KLF5 for Ubiquitin-Mediated Degradation and Suppresses Breast Cell Proliferation
Here, researchers show that the Skp1-CUL1-Fbw7 E3 ubiquitin ligase complex (SCFFbw7) targets KLF5 for ubiquitin-mediated degradation in a GSK3beta-mediated KLF5 phosphorylation-dependent manner. [Cancer Res]

Estrogen Receptor Beta1 Expression is Regulated by miR-92 in Breast Cancer
Here, researchers report that levels of ERbeta1 expression are negatively regulated by the microRNA miR-92. [Cancer Res]

Deregulated Estrogen Receptor Alpha and p53 Heterozygosity Collaborate in the Development of Mammary Hyperplasia
Genetically engineered mouse models of deregulated ERalpha expression and p53 haploinsufficiency were used to investigate similarities and differences of each genetic lesion alone and in combination on mammary preneoplasia development. [Cancer Res]

Therapeutic CDK4/6 Inhibition in Breast Cancer: Key Mechanisms of Response and Failure
Recently, a highly specific inhibitor of CDK4/6 activity (PD-0332991) has been developed that may have efficacy in the treatment of breast cancer. To interrogate the utility of PD-0332991 in treating breast cancers, therapeutic response was evaluated on a panel of breast cancer cell lines. [Oncogene]

Phosphodiesterase Type 5 Inhibitors Increase Herceptin Transport and Treatment Efficacy in Mouse Metastatic Brain Tumor Models
These findings suggest that phosphodiesterase 5 inhibitors may effectively modulate blood-brain tumor barrier permeability, and enhance delivery and therapeutic efficacy of monoclonal antibodies in hard-to-treat brain metastases from different primary tumors that had metastasized to the brain. [PLoS ONE]


Dose-Dense Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel with Trastuzumab and Lapatinib in HER2/Neu-Overexpressed/Amplified Breast Cancer is Not Feasible Because of Excessive Diarrhea
Researchers conducted a pilot study of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab plus lapatinib followed by trastuzumab plus lapatinib. [J Clin Oncol]

Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer
Researchers tested the hypothesis that Akt-Ser473 phosphorylation predicts benefit from the sequential addition of paclitaxel to adjuvant doxorubicin plus cyclophosphamide chemotherapy in patients with node-positive breast cancer participating in the National Surgical Adjuvant Breast and Bowel Project B-28 trial. [J Clin Oncol]

Insulin-Like Growth Factor 1 (IGF1), IGF Binding Protein 3 (IGFBP3), And Breast Cancer Risk: Pooled Individual Data Analysis of 17 Prospective Studies
The Endogenous Hormones and Breast Cancer Collaborative Group was established to analyse pooled individual data from prospective studies to increase the precision of the estimated associations of endogenous hormones with breast-cancer risk. [Lancet Oncol]


Hawthorn Pharmaceuticals and the University of Pittsburgh Sign Exclusive Global Licensing Agreement of CSPG4 Specific Monoclonal Antibodies
Hawthorn Pharmaceuticals, Inc. announced a global licensing deal with the University of Pittsburgh covering a series of novel monoclonal antibodies for cancer. [Hawthorn Pharmaceuticals, Inc. Press Release]

Pixantrone Associated with Up to 4-Fold Reduction in Severe (Grade 3-4) Cardiac Toxicity When Compared to Doxorubicin in CHOP-R Regimen
Cell Therapeutics, Inc. reported preliminary cardiac safety results from a North American randomized phase II trial which substituted pixantrone for doxorubicin in the standard CHOP-R regimen. [Cell Therapeutics, Inc. Press Release]

Abviva Announces Further Patent Issuance for Technology Used In Breast Cancer Diagnostics and Therapeutics
Abviva, Inc. announced that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company’s breast cancer risk assessment test, the Mammastatin Serum Assay. [Biocompare]


Personal Gene-Testing Companies Need U.S. Clearance, FDA Says
Gene-test kits that promise to tell consumers their risk of Alzheimer’s disease, breast cancer and numerous illnesses must be approved by regulators whether the tests are sold online or in stores, a U.S. official said. [Food and Drug Administration, United States]

NIH Starts to Flesh Out Drug Development Program
Lawmakers began discussing the details of a newly created drug development program at the National Institutes of Health (NIH). NIH Director Francis Collins told a Senate panel that he’s eager to get started – once the program has a budget. [National Institutes of Health, United States]

Statement by HHS Secretary Kathleen Sebelius and NIH Director Francis Collins Regarding the President’s Intent to Appoint Dr. Harold Varmus as Director of the National Institute of Cancer at the National Institutes of Health [National Institutes of Health, United States]

Enhancing Peer Review: Expectation for Service on NIH Peer Review and Advisory Groups (NOT-OD-10-089) [National Institutes of Health, United States]

Request for Information: Scientific and Regulatory Issues to be Explored at an Upcoming Pluripotent Stem Cell Workshop Involving NIH and FDA (NOT-NS-10-016) [National Institutes of Health, United States]

Drug Safety and Risk Management Advisory Committee; Notice of Meeting (Docket No. FDA-2010-N-0001) [Food and Drug Administration, United States]

Agency Information Collection Activities; Proposed Collection; Comment Request; Experimental Study of Patient Information Prototypes (Docket No. FDA-2010-N-0184) [Food and Drug Administration, United States]


American Society of Clinical Oncology (ASCO) Annual Meeting 2010
June 4-8, 2010
Chicago, United States

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom


Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Sr. Product Support and Training Specialist (CardianBCT)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us